Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer
By S. Rose‐John, J. Scheller, G. Elson, Simon A. Jones. Journal of Leukocyte Biology, 2006
699 citations recorded by the source corpus.
Subfields: Dermatology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/5ab06a7ab79435a51d88525dfb49030afa0e888d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Dermatology
In Immunology
In Oncology
Citations in the corpus
- A cytokine-mediated link between innate immunity, inflammation, and cancer. (2007, positive): “In addition to classic IL-6 signaling, secretion of soluble IL-6 receptor (sIL-6R) can trigger IL-6 trans -signaling and is critically involved in the development of colon cancer (68).”
- Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “The presence of soluble IL-6R (sIL-6R) also allows IL-6 to function through a pathway known as trans-signaling (Rose-John et al., 2006).”
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 (2012, background): “These results indicated that the IL-6 trans-signaling pathway was used in many cell types and tissues [53].”
- Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. (2011, background): “Because IL-6R is sparsely expressed, IL-6 transsignaling increases the number of potential IL-6 target cells (Rose-John et al., 2006).”
- Inflammatory bone loss: pathogenesis and therapeutic intervention (2012, background): “These cytokines' cognate receptors (α-chains) cannot induce the activation of intracellular signal transduction by themselves; the α-chain–cytokine dimer can recruit gp130 (the β-chain) to form a trimolecular complex or even a hexamolecular moiety (consisting of two trimolecular complexes of the cyt”
- IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. (2007, background): “Introduction IL-6, a major mediator of the inflammatory response, plays a primary role in the pathophysiology of cancer (1, 2).”
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. (2011, methodology): “As noted above, this may in part be regulated by sgp130 variants, which circulate at high levels in human sera and selectively antagonize IL-6 trans-signaling (32).”
- Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training (2013, positive): “As a consequence of receptor shedding, the IL-6/IL6R complex can travel to sites of inflammation or cellular dysfunction and transduce a signal via the gp130R (550).”